Processa Pharmaceuticals will present at the 2025 BIO CEO & Investor Conference and hold one-on-one meetings with investors.
Quiver AI Summary
Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a corporate overview on February 11 at 10:00 a.m. ET and will host one-on-one meetings with registered investors at the event. Processa focuses on developing next-generation cancer therapies with enhanced efficacy and safety, utilizing modifications of existing FDA-approved oncology drugs to improve their effectiveness while minimizing side effects. Interested parties can schedule meetings via the BIO Partnering portal or contact Yvonne Briggs for alternative arrangements. For more details, visit Processa's website.
Potential Positives
- Participation in the 2025 BIO CEO & Investor Conference provides visibility and networking opportunities with key investors and industry leaders.
- Management will present a corporate overview, potentially increasing investor interest and confidence in the company's initiatives and pipeline.
- One-on-one meetings with registered investors may facilitate deeper engagement and discussions about the company's innovative cancer therapies.
- Processa's focus on developing modified FDA-approved oncology therapies positions it to leverage existing regulatory pathways while aiming to enhance treatment efficacy and safety for cancer patients.
Potential Negatives
- Company is a clinical-stage pharmaceutical, indicating it is still in the early stages of drug development, which often involves significant financial risk and uncertainty.
- The focus on modifications of existing FDA-approved drugs may suggest a lack of originality in their therapeutic approach, which could impact investor perception.
- The press release does not highlight any new significant developments or breakthroughs, which may lead to concerns about the company's progress and future prospects.
FAQ
What is the purpose of Processa Pharmaceuticals' participation in the BIO CEO & Investor Conference?
Processa Pharmaceuticals is presenting a corporate overview and meeting investors to discuss their cancer therapies.
When is Processa Pharmaceuticals presenting at the conference?
Processa Pharmaceuticals will present on Tuesday, February 11, 2025, at 10:00 a.m. Eastern time.
How can investors schedule a meeting with Processa management?
Investors can schedule a meeting through the BIO Partnering portal or contact Yvonne Briggs at ybriggs@allianceadvisors.com.
What types of therapies does Processa Pharmaceuticals develop?
Processa develops Next Generation Cancer drugs that improve safety and efficacy using existing FDA-approved oncology therapies.
Where can I find more information about Processa Pharmaceuticals?
More information can be found on their website at www.processapharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PCSA Insider Trading Activity
$PCSA insiders have traded $PCSA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PCSA stock by insiders over the last 6 months:
- DAVID YOUNG (Pres. Research & Development) purchased 124,500 shares for an estimated $99,288
- GEORGE K NG (Chief Executive Officer) purchased 87,200 shares for an estimated $69,542
- PATRICK LIN (Chief Business - Strategy Off) purchased 43,500 shares for an estimated $34,691
- JUSTIN W YORKE purchased 12,400 shares for an estimated $9,889
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCSA Hedge Fund Activity
We have seen 5 institutional investors add shares of $PCSA stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MIRACLE MILE ADVISORS, LLC added 10,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,838
- GEODE CAPITAL MANAGEMENT, LLC added 2,456 shares (+14.2%) to their portfolio in Q3 2024, for an estimated $3,364
- TOWER RESEARCH CAPITAL LLC (TRC) added 641 shares (+21.4%) to their portfolio in Q3 2024, for an estimated $878
- UBS GROUP AG added 521 shares (+inf%) to their portfolio in Q3 2024, for an estimated $713
- MAIN STREET GROUP, LTD removed 100 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $137
- ALLWORTH FINANCIAL LP removed 85 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $75
- ROYAL BANK OF CANADA removed 4 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)
(Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis.
Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the Plymouth Room, and will hold one-on-one meetings with registered investors and other attendees throughout the conference. Those interested in scheduling a meeting with Processa management are encouraged to do so through the BIO Partnering
portal
. For those not attending the conference who are interested in meeting with Processa management, please contact Yvonne Briggs at
ybriggs@allianceadvisors.com
.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at
www.processapharma.com
.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations Contact:
Yvonne Briggs
Alliance Advisors IR
(310) 691-7100
ybriggs@allianceadvisors.com
# # #
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
